Ep. 141: Devon Krantz, Molecule
Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule\u2019s CEO, Devon Krantz, discusses the dire state of pharmacological R&D and its cost\u2014literally and figuratively\u2014to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: \u201cWe are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP, and maybe it's in an underfunded area, and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We\u2019re democratizing access to cures.\u201d Devon elaborates on the innovative and complex \u2018why & how\u2019 during the rest of the conversation.